title: 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
abstract: 5-Fluorouracil (5-FU)-related early toxicity, due to a metabolic deficiency, is rare but is potentially severe and even lethal (0.1%). It is due to dihydropyrimidine dehydrogenase (DPYD) gene polymorphism or some epigenetic factors. The detection of metabolic change could prevent severe toxicity, but until now it has not been carried out in clinical practice.
  
  
  OBJECTIVE
  To find the simplest and most accurate pretherapeutic test to predict DPD deficiency in patients treated with 5-FU by comparing different approaches.
  
  
  RESULTS
  Two hundred and fifty two French Caucasian patients treated by 5-FU infusion were studied. A two-step strategy, combining firstly SNP detection and uracil plasma measurement, followed, in cases where metabolic deficiency was suspected, by dihydrouracil/uracil ratio determination to confirm deficiency and to determine the optimum 5-FU dosage, appeared the best approach, with 83% and 82% sensitivity and specificity, respectively.
  
  
  CONCLUSIONS
  These data support the future use of this approach, suitable to clinical practice, as screening test to identify DPD deficiency before 5-FU-based therapy.
authors.affiliation: Oncopharmacology and Pharmacogenetic Laboratory, INSERM U564, Centre Paul Papin, 2 rue Moll, 49933 Angers cedex 9, France.
authors.forename: M
authors.initials: M
authors.lastname: Boisdron-Celle
authors.forename: G
authors.initials: G
authors.lastname: Remaud
authors.forename: S
authors.initials: S
authors.lastname: Traore
authors.forename: A L
authors.initials: AL
authors.lastname: Poirier
authors.forename: L
authors.initials: L
authors.lastname: Gamelin
authors.forename: A
authors.initials: A
authors.lastname: Morel
authors.forename: E
authors.initials: E
authors.lastname: Gamelin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000493:pharmacokinetics; D054067:Dihydropyrimidine Dehydrogenase Deficiency; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects* / Q000493:pharmacokinetics; D005820:Genetic Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D014498:Uracil / Q000031:analogs & derivatives / Q000097:blood
chemical_list: D000964:Antimetabolites, Antineoplastic; D012333:RNA, Messenger; C007419:dihydrouracil; D014498:Uracil; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil